Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

10/22/2021 | 07:05pm EST

BB Biotech AG reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was CHF 208.4 million compared to CHF 395.22 million a year ago. Basic loss per share from continuing operations was CHF 3.76 compared to CHF 7.13 a year ago. Diluted loss per share from continuing operations was CHF 3.76 compared to CHF 7.13 a year ago. For the nine months, revenue was CHF 187.17 million compared to CHF 61.97 million a year ago. Net income was CHF 141.1 million compared to CHF 26.49 million a year ago. Basic earnings per share from continuing operations was CHF 2.55 compared to CHF 0.48 a year ago. Diluted earnings per share from continuing operations was CHF 2.55 compared to CHF 0.48 a year ago.


ę S&P Capital IQ 2021
All news about BB BIOTECH AG
10/22BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
10/22BB BIOTECH : Q3 Net Loss Shrinks
MT
10/22BB BIOTECH : increases positions in oncology and CNS
PU
10/22BB BIOTECH : publishes its interim report
EQ
10/22BB BIOTECH : Gains realized following COVID-19 vaccine booster update enable increases in ..
EQ
07/23Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/23BB BIOTECH : Posts Lower H1 Profit, Operating Income
MT
07/23BB BIOTECH : Interim report as at June 30, 2021
PU
07/23BB BIOTECH : publishes its interim report
EQ
07/23BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
EQ
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Financials
Sales 2021 -87,5 M -95,0 M -95,0 M
Net income 2021 439 M 477 M 477 M
Net Debt 2021 23,5 M 25,5 M 25,5 M
P/E ratio 2021 7,63x
Yield 2021 5,18%
Capitalization 4 299 M 4 663 M 4 669 M
EV / Sales 2021 -49,4x
EV / Sales 2022 -
Nbr of Employees 10
Free-Float 98,1%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 77,60 CHF
Average target price 97,00 CHF
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG4.32%4 625
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-42.20%23 611